Vol. 6, Issue 1, Part A (2024)

Back ground: The prevalence of chronic kidney disease (CKD) is rising, making it a major healthcare issue. Kidney fibrosis is the result of the majority of chronic kidney injury, regardless of its cause. Due to its distinct binding profile, pentraxin-2 may accumulate at sites of injury and aid in the non-phlogistic removal of injured tissue. Serum PTX-2 levels may drop in some fibrotic conditions such idiopathic pulmonary fibrosis, nonalcoholic steatohepatitis, and end-stage renal disease as a result of ongoing PTX-2 production and use.

Methods: In a cross-sectional study, 30 healthy people served as control group for the marker only and 60 patients had a reason for a kidney biopsy. The same pathologist assessed the degree of renal fibrosis using the Banff scoring system for glomerulosclerosis (GS) and interstitial fibrosis and tubular atrophy (IFTA). An enzyme-linked immunosorbent test was used to quantify PTX-2, and the results were compared with the patients' biochemical, histological, clinical, and demographic information.

Results: Serum PTX-2 levels decrease significantly in patients group than control group but PTX 2 levels were statistically insignificant between grades of IFTA and GS.

Conclusion: Serum PTX-2 isn’t significantly associated with degree of renal fibrosis.